Alliancebernstein L.P. Sells 18,274 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Alliancebernstein L.P. reduced its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 9.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 175,428 shares of the company’s stock after selling 18,274 shares during the period. Alliancebernstein L.P.’s holdings in Teva Pharmaceutical Industries were worth $3,866,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Wilmington Savings Fund Society FSB acquired a new stake in Teva Pharmaceutical Industries during the third quarter worth approximately $50,000. Ameliora Wealth Management Ltd. acquired a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $66,000. IFP Advisors Inc boosted its holdings in shares of Teva Pharmaceutical Industries by 96.1% during the 4th quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after buying an additional 1,960 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $104,000. Finally, Assetmark Inc. increased its stake in shares of Teva Pharmaceutical Industries by 1,370.3% in the 4th quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock valued at $115,000 after acquiring an additional 4,851 shares in the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Trading Up 0.9 %

TEVA opened at $13.58 on Tuesday. Teva Pharmaceutical Industries Limited has a fifty-two week low of $12.47 and a fifty-two week high of $22.80. The firm has a market capitalization of $15.40 billion, a PE ratio of -9.37, a P/E/G ratio of 1.44 and a beta of 0.72. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The company’s 50-day moving average is $15.71 and its 200 day moving average is $17.79.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, research analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on TEVA shares. Bank of America cut their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday, March 6th. StockNews.com cut shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Monday. UBS Group reduced their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Piper Sandler upped their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Finally, Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.